This is a StreetInsider.com Premium Only Page

(ATXI) – StreetInsider.com Reports

Apr 24, 2024 07:31 AM Avenue Therapeutics (ATXI) Announces 1:75 Reverse Share Split

Mar 15, 2024 08:16 AM Avenue Therapeutics (ATXI) Receives Positive Nasdaq Listing Determination

Mar 8, 2024 04:46 PM Avenue Therapeutics (ATXI) to Execute 1:30 to 1:75 Reverse Share Split

Feb 22, 2024 08:32 AM Avenue Therapeutics (ATXI) Reports Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101

Jan 24, 2024 04:15 PM Avenue Therapeutics (ATXI) Announces 33.08M Share Offering by Selling Stockholders

Jan 5, 2024 09:16 AM Avenue Therapeutics (ATXI) Enters Warrant Exercise Transactions for $5.0M in Proceeds

Jan 4, 2024 08:31 AM Avenue Therapeutics (ATXI) Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

Dec 11, 2023 08:04 AM Maxim Group Starts Avenue Therapeutics (ATXI) at Buy

Nov 14, 2023 04:03 AM Avenue Therapeutics (ATXI) Tops Q3 EPS by 34c

Oct 31, 2023 09:18 AM Avenue Therapeutics (ATXI) Announces Pricing of $5.0 Million Public Offering

Oct 2, 2023 02:38 AM Avenue Therapeutics (ATXI) Announces 21.35M Unit Offering

Aug 11, 2023 05:33 AM Avenue Therapeutics (ATXI) Misses Q2 EPS by 39c

Aug 1, 2023 08:31 AM Avenue Therapeutics (ATXI) Announces High Potency and Full Efficacy in a Model of Generalized Seizures for BAER-101

Jul 25, 2023 08:31 AM Avenue Therapeutics (ATXI) Reaches Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol

Jun 20, 2023 06:19 AM Avenue Therapeutics (ATXI) Announces 1.11M Share Offering by Selling Stockholders

Apr 18, 2023 06:54 AM Avenue Therapeutics (ATXI) gains following 'very productive' FDA Type C Meeting on IV Tramadol

Apr 17, 2023 04:02 PM Avenue Therapeutics (ATXI) Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol

Apr 11, 2023 06:05 AM Avenue Therapeutics (ATXI) Announces 1.94M Share Offering by Selling Stockholders

Mar 10, 2023 07:12 AM Avenue Therapeutics (ATXI) Announced Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201

Mar 8, 2023 04:04 PM Avenue Therapeutics (ATXI) will participate in a Type C meeting with the FDA on March 9

Mar 6, 2023 12:28 PM Aegis Capital Starts Avenue Therapeutics (ATXI) at Buy

Mar 2, 2023 08:01 AM Avenue Therapeutics (ATXI) Enters into License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201

Jan 27, 2023 11:59 AM Avenue Therapeutics (ATXI) Announces $3.25 Million Registered Direct and Private Placement of Common Stock, Warrants

Jan 17, 2023 04:29 PM U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 1.14%

Oct 7, 2022 06:09 AM Avenue Therapeutics (ATXI) Prices 3.63M Share Offering at $3.30/sh

Sep 27, 2022 04:47 PM U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.43%

Sep 22, 2022 05:46 PM After-Hours Movers: Spectrum Pharm Sinks on Negative FDA Panel, Costco Dips on EPS

Sep 22, 2022 04:25 PM Avenue Therapeutics (ATXI) Announces 1-for-15 Reverse Stock Split, Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from FDA

Mar 31, 2022 07:34 AM Abeona Therapeutics (ABEO) Announces Strategy Update and 2021 Financial Results

Mar 30, 2022 05:06 PM Avenue Therapeutics (ATXI) Announces CEO Resignation

Mar 9, 2022 04:24 PM Abeona Therapeutics (ABEO) CFO to Resign

Mar 1, 2022 09:51 AM Avenue Therapeutics (ATXI) Halted on Volatility, Up 230%

Feb 16, 2022 09:20 AM Pre-Open Stock Movers 02/16: (HOOK) (UPST) (AYX) Higher; (ATXI) (MASI) (WIX) Lower (more...)

Feb 16, 2022 06:57 AM Avenue Therapeutics (ATXI) to Resume Trading at 7:10 a.m.

Feb 16, 2022 05:54 AM Avenue Therapeutics (ATXI) Announces FDA Adcom Voted 14 No to 8 Yes on IV Tramadol

Feb 15, 2022 07:06 AM Avenue Therapeutics (ATXI) Stock Trading Halted Today Ahead of FDA Advisory Committee Meeting

Feb 15, 2022 06:55 AM Avenue Therapeutics (ATXI) Halted, News Pending

Dec 13, 2021 04:55 AM Avenue Therapeutics (ATXI) Prices 1.91M Share Offering at $1.07/sh

Dec 7, 2021 04:35 PM Avenue Therapeutics (ATXI) Files $30M Mixed Shelf

Nov 29, 2021 08:01 AM Avenue Therapeutics (ATXI) Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022

Nov 10, 2021 09:19 AM Pre-Open Movers 11/10: (PUBM) (RNG) (DASH) Higher; (PRPL) (POSH) (UPST) Lower (more...)

Nov 10, 2021 05:43 AM Avenue Therapeutics (ATXI) Prices 1.95M Share Offering at $1.34/sh

Oct 25, 2021 07:04 AM Avenue Therapeutics (ATXI) Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs

Jun 14, 2021 09:27 AM Pre-Open Stock Movers 06/14: (RAPT) (CRSR) (RIOT) Higher; (ATXI) (RIDE) (RACE) Lower (more...)

Jun 14, 2021 08:15 AM U.S. FDA declines to approve Avenue's IV formulation of painkiller

Jun 14, 2021 07:01 AM Avenue Therapeutics (ATXI) Receives CRL from the FDA for IV Tramadol

Jun 14, 2021 06:56 AM Avenue Therapeutics (ATXI) Halted, News Pending

Apr 13, 2021 11:06 AM Fortress Biotech (FBIO) Reaction 'Overdone' - Cantor Fitzgerald

Apr 13, 2021 06:31 AM Avenue Therapeutics (ATXI) Announces FDA is Still Reviewing Its NDA Resubmission for IV Tramadol

Dec 18, 2020 08:02 AM Avenue Therapeutics (ATXI) Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network